ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO837

Urinary Tract Infections in the First Year After Renal Transplantation in Current of Immunosuppression Setting: A 5-Year Retrospective Single-Centre Study

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical

Authors

  • Andrade, Jorge Carlos, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
  • Andrade-Sierra, Jorge, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico
  • Fuentes Lopez, Elsa Angelica, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
  • Rojas-Campos, Enrique, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
  • Martinez, Manuel, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
  • Cerrillos, Jose Ignacio, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
  • Evangelista-Carrillo, Luis Alberto, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
Background

Urinary tract infection (UTI) is associated with development impaired allograft function. Our objective was assessing to UTI risk factors and its impact in the allograft function.

Methods

Retrospective Cohort from March-2014 to March-2019 included 1341 patients with kidney transplantation. All patients with development at least one UTI event during first year after transplantation were registered. Prophylaxis with TMP-SMX (160/800mg) was used for 3-6 months and the main immunosuppression scheme was based on TAC/MMF/PDN.

Results

The accumulated incidence of UTI was 41% and ESBL-producing Escherichia Coli was the most frequent agent causing. In a Logistic Regression analysis; risks factors were Anti-thymocyte globulin (ATG) (RR 1.5; 1.18-1.91; p=0.001), surgical complications (RR 2.4; 1.7-3.4; p=0.001), duration of bladder catheterization (RR 1.43; 1.09-1.9; p= 0.021), transplant number (RR 1.8; 1.09-3.0; p=0.001).

Conclusion

Despite the high incidence of UTI, there was no impact on graft function at 12 months post transplantation. Use of ATG and prolonged bladder catheterization are some of the risk factors.

 UTI=548No UTI=793P
Age (years)32 ± 1230 ± 100.003
Male-gender n (%)344 (62.8)582 (73.4)0.001
Induction, n (%)   
ATG
Basiliximab
322 (59)
226 (41)
507 (64)
286 (36)
0.059
Type of Donor (%)   
Living donor
Deseaced donor
462 (84)
86 (15.7)
690 (87)
103 (13)
NS
Transplant n (%)   
First
Second
509 (93)
39 (7)
758 (95.6)
35 (4.4)
NS
Double J stent n (%)125 (22.8)124 (15.6)0.006
Bladder catheterization Time n (%)   
< 5
6-7
7-14
>14
368 (67.2)
144 (26.3)
28 (5.0)
8 (1.5)
624 (78.7)
142 (17.9)
24 (3.0)
3 (0.4)
0.001
CrS at 12-months (mg/dL)1.14 ± 0.581.23 ± 1.25NS